SRB123-ADC
Category
Drugs National Companies
Register type
Biotech Sanitaria
Company name
Product / Service
SRB123-ADC
Type
Biodrugs/ Drugs
Therapeutic area
Oncología
Properties/Indication
First-in-class antibody-drug conjugate (ADC) directed against the CCR9 chemokine receptor using Escugen's EZWi-Fit® linker-payload platform for the treatment of pancreatic, ovarian and lung tumors.
Application
Pancreatic, ovarian and lung tumors
Development phase
Preclinical
Industrial property
✔
Patent
✔